Global Cystic Fibrosis Therapeutics Market By Test (Sweat Test, Genetic Test, DNA test, Newborn Screening, Chest X-ray, Others)By Treatments( Medications(Antibiotics, Anti-inflammatory Drugs, Bronchodilators, CFTR Modulators, Mucus Thinning Medications, Others) Surgery(Nasal and Sinus Surgery, Bowel Surgery, Liver Transplant, Lung Transplant, Others)) By Route Of Administration (Oral, Inhaled) By Age Group (Pediatrics, Adults, Geriatric) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
A genetic condition known as cystic fibrosis (CF) damages the body's secretory glands, including the lungs, pancreas, liver, and intestines. In lungs, this illness is most prevalent. Cystic fibrosis causes irregular discharges that cause mucus to accumulate and prevent the affected organ from functioning properly. Physical therapy for cystic fibrosis patients helps to loosen mucus, and medicines and enzymes are used to fight off infections in organs. A gene necessary for the protein cystic fibrosis transmembrane conductance regulator is mutated, which results in the disease (CFTR). Sweat, mucus, and bodily fluids are controlled by CFTR. The development of a novel medication with improved efficacy and outcomes is anticipated to present a good growth potential for the cystic fibrosis therapeutics market. Additionally, because of their sizable population bases and expanding economies, emerging markets have a particularly high potential for growth for cystic fibrosis medicines. The launch of numerous medications in the antibiotics sector is one of the key growth trends in the cystic fibrosis therapeutics market.
Another significant factor that is anticipated to promote cystic fibrosis therapeutics market growth is the rising knowledge of oral medication therapies, such as pancreatic enzyme supplements and CFTR modulators for cystic fibrosis, in emerging nations. To improve public health, many medical institutions and healthcare groups raise knowledge of cystic fibrosis treatment options. The cystic fibrosis foundation used social media to raise awareness of cystic fibrosis by posting personal accounts of diagnosis, treatment options, and other topics. Thus, rising awareness and emerging therapeutic treatments, the cystic fibrosis therapeutics market is expected to flourish in the upcoming year globally.
In terms of revenue, global cystic fibrosis therapeutics market was valued at US$ 9.5 Bn in 2021, growing at a CAGR of 16.9% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Cystic Fibrosis Therapeutics Market Revenue & Forecast, (US$ Million), 2015 – 2030
Treatments Outlook
Based on the drug class, the global cystic fibrosis market is segmented into medications and surgeries wherein medication such as antibiotics, bronchodilators, anti-inflammatory drugs and CFTR modulators, among other drugs, serve to lessen respiratory symptoms and lung flare-ups while also improving patients' short-term quality of life. These elements raise the demand for medicines. Other elements include escalating demand and increased knowledge of cutting-edge drugs are encouraging the industry growth. The commercialization of cystic fibrosis treatments will be impacted further by new product introductions and regulatory approvals. In the last few years, CFTR modulator therapies have gained huge momentum as these drugs represent an extraordinary advance in management of cystic fibrosis (CF). The triple combination of the approved modulators elexacaftor, tezacaftor, and ivacaftor is the most frequently utilised (ETI). Ivacaftor monotherapy and the dual regimens of tezacaftor and ivacaftor, as well as lumacaftor and ivacaftor, are further approved modulators. The CFTR gene mutations in a particular patient determines their indications and efficacy. Hence, in the upcoming years due to the advancements in drug class it is expected that the cystic fibrosis therapeutics market will boost during the forecast period 2022-2030.
Age Group
Based on the age group segment, the global cystic fibrosis therapeutics market is segmented into children, adults and geriatric. The majority of CF cases in children are discovered by the age of 2, in large part due to newborn screening programmes implemented globally. A tiny percentage of people do not have symptoms until they are 18 or older. These kids typically have a milder form of the illness. In 2019, Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination medication available to treat patients with the most prevalent cystic fibrosis mutation, was approved by the U.S. Food and Drug Administration. Patients with cystic fibrosis aged 12 years and older who have at least one F508del mutation in the CFTR gene, which is thought to account for 90% of those with the disease, are eligible to receive Trikafta. Thus, with emerging therapeutics for different set of age groups, the cystic fibrosis therapeutics market is experiencing an upsurge in growth.
Region Outlook
Based on the regions, North America registered for the highest share in the cystic fibrosis therapeutics market in the year 2021. The cystic fibrosis therapeutics market is driven by rising government initiatives such increased funding for new technologies and R&D research on cystic fibrosis drugs. For instance, the North American Cystic Fibrosis Conference (NACFC) provides a venue for experts in disease to discuss advancements in research and development (R&D) pertaining to cystic fibrosis medicines. Over the projected timeframe, other variables like reimbursements, the presence of significant industry leaders, and well-established healthcare infrastructure will drive demand in the North American market.
Competitive Landscape
The report provides both, qualitative and quantitative research of cystic fibrosis therapeutics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
A few of the key players operating in the global cystic fibrosis therapeutics market are listed below:
- AbbVie Inc.
- Alaxia
- Alcresta Therapeutics, Inc
- CHIESI Farmaceutici S.p.A
- Genentech, Inc.
- Gilead Sciences, Inc.
- Horizon Therapeutics plc
- Laurent Pharmaceuticals Inc
- Mylan N.V.
- Novartis AG
- Pharmaxis Ltd
- Teva UK Limited
- Vertex Pharmaceuticals Incorporated
- Other Market Participants
Global Cystic Fibrosis Therapeutics Market:
By Test
- Sweat Test
- Genetic Test
- DNA Test
- Newborn Screening
- Chest X-ray
- Others
By Treatment
- Medications
- Antibiotics
- Anti-inflammatory drugs
- Bronchodilators
- CFTR modulators
- Mucus thinning medications
- Others
- Surgery
- Nasal and sinus surgery
- Bowel Surgery
- Liver transplant
- Lung transplant
- Others
By Route Of Administration
- Oral
- Inhaled
By Age Group
- Pediatrics
- Adults
- Geriatric
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Cystic Fibrosis Therapeutics Market
6.
Market
Synopsis:Â Cystic Fibrosis Therapeutics
Market
7.
Cystic
Fibrosis Therapeutics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Cystic Fibrosis Therapeutics Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Cystic Fibrosis Therapeutics Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Cystic Fibrosis
Therapeutics Market
8.
Global Cystic
Fibrosis Therapeutics Market Analysis and Forecasts, 2022 - 2030
8.1. Overview
8.1.1. Global Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn)
8.2. Global Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By TestÂ
8.2.1. Sweat test
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. Genetic test
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.2.3. DNA test
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 - 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 - 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 - 2030
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 - 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 - 2030
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 - 2030
8.2.4. Newborn Screening
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 - 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 - 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 - 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 - 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 - 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 - 2030
8.2.5. Chest X-ray
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 - 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 - 2030
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 - 2030
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 - 2030
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 - 2030
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 - 2030
8.2.6. Others
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.6.3.
Market
Forecast, 2022 - 2030
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2021
8.2.6.5.1.2. Market Forecast, 2022 - 2030
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2021
8.2.6.5.2.2. Market Forecast, 2022 - 2030
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2021
8.2.6.5.3.2. Market Forecast, 2022 - 2030
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2021
8.2.6.5.4.2. Market Forecast, 2022 - 2030
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2021
8.2.6.5.5.2. Market Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By TestÂ
9.
Global Cystic
Fibrosis Therapeutics Market Analysis and Forecasts, 2022 - 2030
9.1. Overview
9.2. Global Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Treatments
9.2.1. MedicationsÂ
(Definition, Market Estimation and Penetration, 2015 - 2021, Market
Estimation (2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Antibiotics ,
Anti-inflammatory drugs, Bronchodilators, CFTR modulators, Mucus thinning
medications , Others)
9.2.1.1.
Antibiotics
9.2.1.2.
Anti-inflammatory
drugs
9.2.1.3.
Bronchodilators
9.2.1.4.
CFTR modulators
9.2.1.5.
Mucus
thinning medications
9.2.1.6.
Others
9.2.2. SurgeryÂ
(Definition, Market Estimation and Penetration, 2015 - 2021, Market
Estimation (2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Nasal and sinus surgery,
Bowel Surgery, Liver transplant , Lung transplant , Others)
9.2.2.1.
Nasal
and sinus surgery
9.2.2.2.
Bowel
Surgery
9.2.2.3.
Liver
transplant
9.2.2.4.
Lung
transplant
9.2.2.5.
Others
9.3. Key Segment for Channeling Investments
9.3.1. By Treatments
10. Global Cystic Fibrosis Therapeutics Market
Analysis and Forecasts, 2022 - 2030
10.1. Overview
10.2. Global Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route Of Administration
10.2.1. Oral
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 - 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Inhaled
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 - 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Route Of Administration
11. Global Cystic Fibrosis Therapeutics Market
Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.2. Global Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Age Group
11.2.1. Pediatrics
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 - 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 - 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 - 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 - 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 - 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 - 2030
11.2.2. Adults
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 - 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 - 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 - 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 - 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 - 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 - 2030
11.2.3. Geriatric
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.3.3.
Market
Forecast, 2022 - 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 - 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 - 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 - 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 - 2030
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 - 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Age Group
12. North America Cystic Fibrosis Therapeutics
Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. North America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn)
12.2. North America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By TestÂ
12.2.1. Sweat test
12.2.2. Genetic test
12.2.3. DNA test
12.2.4. Newborn Screening
12.2.5. Chest X-ray
12.2.6. Others
12.3. North America Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Treatments
12.3.1. Medications
12.3.1.1.
Antibiotics
12.3.1.2.
Anti-inflammatory
drugs
12.3.1.3.
Bronchodilators
12.3.1.4.
CFTR
modulators
12.3.1.5.
Mucus
thinning medications
12.3.1.6.
Others
12.3.2. Surgery
12.3.2.1.
Nasal
and sinus surgery
12.3.2.2.
Bowel
Surgery
12.3.2.3.
Liver
transplant
12.3.2.4.
Lung
transplant
12.3.2.5.
Others
12.4. North America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route Of Administration
12.4.1. Oral
12.4.2. Inhaled
12.5. North America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Age Group
12.5.1. Pediatrics
12.5.2. Adults
12.5.3. Geriatric
12.6. North America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
12.6.1.1.1.
Sweat
test
12.6.1.1.2.
Genetic
test
12.6.1.1.3.
DNA test
12.6.1.1.4.
Newborn
Screening
12.6.1.1.5.
Chest
X-ray
12.6.1.1.6.
Others
12.6.1.2.
U.S Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
12.6.1.2.1.
Medications
12.6.1.2.1.1. Antibiotics
12.6.1.2.1.2. Anti-inflammatory drugs
12.6.1.2.1.3. Bronchodilators
12.6.1.2.1.4. CFTR modulators
12.6.1.2.1.5. Mucus thinning medications
12.6.1.2.1.6. Others
12.6.1.2.2.
Surgery
12.6.1.2.2.1. Nasal and sinus surgery
12.6.1.2.2.2. Bowel Surgery
12.6.1.2.2.3. Liver transplant
12.6.1.2.2.4. Lung transplant
12.6.1.2.2.5. Others
12.6.1.3.
U.S Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
12.6.1.3.1.
Oral
12.6.1.3.2.
Inhaled
12.6.1.4.
U.S Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
12.6.1.4.1.
Pediatrics
12.6.1.4.2.
Adults
12.6.1.4.3.
Geriatric
12.6.2. Canada
12.6.2.1.
Canada Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
12.6.2.1.1.
Sweat
test
12.6.2.1.2.
Genetic
test
12.6.2.1.3.
DNA test
12.6.2.1.4.
Newborn
Screening
12.6.2.1.5.
Chest
X-ray
12.6.2.1.6.
Others
12.6.2.2.
Canada Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
12.6.2.2.1.
Medications
12.6.2.2.1.1. Antibiotics
12.6.2.2.1.2. Anti-inflammatory drugs
12.6.2.2.1.3. Bronchodilators
12.6.2.2.1.4. CFTR modulators
12.6.2.2.1.5. Mucus thinning medications
12.6.2.2.1.6. Others
12.6.2.2.2.
Surgery
12.6.2.2.2.1. Nasal and sinus surgery
12.6.2.2.2.2. Bowel Surgery
12.6.2.2.2.3. Liver transplant
12.6.2.2.2.4. Lung transplant
12.6.2.2.2.5. Others
12.6.2.3.
Canada Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
12.6.2.3.1.
Oral
12.6.2.3.2.
Inhaled
12.6.2.4.
Canada Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
12.6.2.4.1.
Pediatrics
12.6.2.4.2.
Adults
12.6.2.4.3.
Geriatric
12.6.3. Mexico
12.6.3.1.
Mexico Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
12.6.3.1.1.
Sweat
test
12.6.3.1.2.
Genetic
test
12.6.3.1.3.
DNA test
12.6.3.1.4.
Newborn
Screening
12.6.3.1.5.
Chest
X-ray
12.6.3.1.6.
Others
12.6.3.2.
Mexico Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
12.6.3.2.1.
Medications
12.6.3.2.1.1. Antibiotics
12.6.3.2.1.2. Anti-inflammatory drugs
12.6.3.2.1.3. Bronchodilators
12.6.3.2.1.4. CFTR modulators
12.6.3.2.1.5. Mucus thinning medications
12.6.3.2.1.6. Others
12.6.3.2.2.
Surgery
12.6.3.2.2.1. Nasal and sinus surgery
12.6.3.2.2.2. Bowel Surgery
12.6.3.2.2.3. Liver transplant
12.6.3.2.2.4. Lung transplant
12.6.3.2.2.5. Others
12.6.3.3.
Mexico Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
12.6.3.3.1.
Oral
12.6.3.3.2.
Inhaled
12.6.3.4.
Mexico Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
12.6.3.4.1.
Pediatrics
12.6.3.4.2.
Adults
12.6.3.4.3.
Geriatric
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By TestÂ
12.6.4.1.1.
Sweat
test
12.6.4.1.2.
Genetic
test
12.6.4.1.3.
DNA test
12.6.4.1.4.
Newborn
Screening
12.6.4.1.5.
Chest
X-ray
12.6.4.1.6.
Others
12.6.4.2.
Rest of
North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Treatments
12.6.4.2.1.
Medications
12.6.4.2.1.1. Antibiotics
12.6.4.2.1.2. Anti-inflammatory drugs
12.6.4.2.1.3. Bronchodilators
12.6.4.2.1.4. CFTR modulators
12.6.4.2.1.5. Mucus thinning medications
12.6.4.2.1.6. Others
12.6.4.2.2.
Surgery
12.6.4.2.2.1. Nasal and sinus surgery
12.6.4.2.2.2. Bowel Surgery
12.6.4.2.2.3. Liver transplant
12.6.4.2.2.4. Lung transplant
12.6.4.2.2.5. Others
12.6.4.3.
Rest of
North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Route Of Administration
12.6.4.3.1.
Oral
12.6.4.3.2.
Inhaled
12.6.4.4.
Rest of
North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Age Group
12.6.4.4.1.
Pediatrics
12.6.4.4.2.
Adults
12.6.4.4.3.
Geriatric
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By TestÂ
12.7.3. By Treatments
12.7.4. By Route Of Administration
12.7.5. By Age Group
13. Europe Cystic Fibrosis Therapeutics Market
Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Europe Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn)
13.2. Europe Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By TestÂ
13.2.1. Sweat test
13.2.2. Genetic test
13.2.3. DNA test
13.2.4. Newborn Screening
13.2.5. Chest X-ray
13.2.6. Others
13.3. Europe Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Treatments
13.3.1. Medications
13.3.1.1.
Antibiotics
13.3.1.2.
Anti-inflammatory
drugs
13.3.1.3.
Bronchodilators
13.3.1.4.
CFTR
modulators
13.3.1.5.
Mucus
thinning medications
13.3.1.6.
Others
13.3.2. Surgery
13.3.2.1.
Nasal
and sinus surgery
13.3.2.2.
Bowel
Surgery
13.3.2.3.
Liver
transplant
13.3.2.4.
Lung
transplant
13.3.2.5.
Others
13.4. Europe Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route Of Administration
13.4.1. Oral
13.4.2. Inhaled
13.5. Europe Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Age Group
13.5.1. Pediatrics
13.5.2. Adults
13.5.3. Geriatric
13.6. Europe Cystic Fibrosis Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1.
France Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
13.6.1.1.1.
Sweat
test
13.6.1.1.2.
Genetic
test
13.6.1.1.3.
DNA test
13.6.1.1.4.
Newborn
Screening
13.6.1.1.5.
Chest
X-ray
13.6.1.1.6.
Others
13.6.1.2.
France Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
13.6.1.2.1.
Medications
13.6.1.2.1.1. Antibiotics
13.6.1.2.1.2. Anti-inflammatory drugs
13.6.1.2.1.3. Bronchodilators
13.6.1.2.1.4. CFTR modulators
13.6.1.2.1.5. Mucus thinning medications
13.6.1.2.1.6. Others
13.6.1.2.2.
Surgery
13.6.1.2.2.1. Nasal and sinus surgery
13.6.1.2.2.2. Bowel Surgery
13.6.1.2.2.3. Liver transplant
13.6.1.2.2.4. Lung transplant
13.6.1.2.2.5. Others
13.6.1.3.
France Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
13.6.1.3.1.
Oral
13.6.1.3.2.
Inhaled
13.6.1.4.
France Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.1.4.1.
Pediatrics
13.6.1.4.2.
Adults
13.6.1.4.3.
Geriatric
13.6.2. The UK
13.6.2.1.
The UK Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
13.6.2.1.1.
Sweat
test
13.6.2.1.2.
Genetic
test
13.6.2.1.3.
DNA test
13.6.2.1.4.
Newborn
Screening
13.6.2.1.5.
Chest
X-ray
13.6.2.1.6.
Others
13.6.2.2.
The UK Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
13.6.2.2.1.
Medications
13.6.2.2.1.1. Antibiotics
13.6.2.2.1.2. Anti-inflammatory drugs
13.6.2.2.1.3. Bronchodilators
13.6.2.2.1.4. CFTR modulators
13.6.2.2.1.5. Mucus thinning medications
13.6.2.2.1.6. Others
13.6.2.2.2.
Surgery
13.6.2.2.2.1. Nasal and sinus surgery
13.6.2.2.2.2. Bowel Surgery
13.6.2.2.2.3. Liver transplant
13.6.2.2.2.4. Lung transplant
13.6.2.2.2.5. Others
13.6.2.3.
The UK Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
13.6.2.3.1.
Oral
13.6.2.3.2.
Inhaled
13.6.2.4.
The UK Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.2.4.1.
Pediatrics
13.6.2.4.2.
Adults
13.6.2.4.3.
Geriatric
13.6.3. Spain
13.6.3.1.
Spain Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
13.6.3.1.1.
Sweat
test
13.6.3.1.2.
Genetic
test
13.6.3.1.3.
DNA test
13.6.3.1.4.
Newborn
Screening
13.6.3.1.5.
Chest
X-ray
13.6.3.1.6.
Others
13.6.3.2.
Spain Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
13.6.3.2.1.
Medications
13.6.3.2.1.1. Antibiotics
13.6.3.2.1.2. Anti-inflammatory drugs
13.6.3.2.1.3. Bronchodilators
13.6.3.2.1.4. CFTR modulators
13.6.3.2.1.5. Mucus thinning medications
13.6.3.2.1.6. Others
13.6.3.2.2.
Surgery
13.6.3.2.2.1. Nasal and sinus surgery
13.6.3.2.2.2. Bowel Surgery
13.6.3.2.2.3. Liver transplant
13.6.3.2.2.4. Lung transplant
13.6.3.2.2.5. Others
13.6.3.3.
Spain Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
13.6.3.3.1.
Oral
13.6.3.3.2.
Inhaled
13.6.3.4.
Spain Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.3.4.1.
Pediatrics
13.6.3.4.2.
Adults
13.6.3.4.3.
Geriatric
13.6.4. Germany
13.6.4.1.
Germany Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
13.6.4.1.1.
Sweat
test
13.6.4.1.2.
Genetic
test
13.6.4.1.3.
DNA test
13.6.4.1.4.
Newborn
Screening
13.6.4.1.5.
Chest
X-ray
13.6.4.1.6.
Others
13.6.4.2.
Germany Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
13.6.4.2.1.
Medications
13.6.4.2.1.1. Antibiotics
13.6.4.2.1.2. Anti-inflammatory drugs
13.6.4.2.1.3. Bronchodilators
13.6.4.2.1.4. CFTR modulators
13.6.4.2.1.5. Mucus thinning medications
13.6.4.2.1.6. Others
13.6.4.2.2.
Surgery
13.6.4.2.2.1. Nasal and sinus surgery
13.6.4.2.2.2. Bowel Surgery
13.6.4.2.2.3. Liver transplant
13.6.4.2.2.4. Lung transplant
13.6.4.2.2.5. Others
13.6.4.3.
Germany Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
13.6.4.3.1.
Oral
13.6.4.3.2.
Inhaled
13.6.4.4.
Germany Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.4.4.1.
Pediatrics
13.6.4.4.2.
Adults
13.6.4.4.3.
Geriatric
13.6.5. Italy
13.6.5.1.
Italy Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
13.6.5.1.1.
Sweat
test
13.6.5.1.2.
Genetic
test
13.6.5.1.3.
DNA test
13.6.5.1.4.
Newborn
Screening
13.6.5.1.5.
Chest
X-ray
13.6.5.1.6.
Others
13.6.5.2.
Italy Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
13.6.5.2.1.
Medications
13.6.5.2.1.1. Antibiotics
13.6.5.2.1.2. Anti-inflammatory drugs
13.6.5.2.1.3. Bronchodilators
13.6.5.2.1.4. CFTR modulators
13.6.5.2.1.5. Mucus thinning medications
13.6.5.2.1.6. Others
13.6.5.2.2.
Surgery
13.6.5.2.2.1. Nasal and sinus surgery
13.6.5.2.2.2. Bowel Surgery
13.6.5.2.2.3. Liver transplant
13.6.5.2.2.4. Lung transplant
13.6.5.2.2.5. Others
13.6.5.3.
Italy Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
13.6.5.3.1.
Oral
13.6.5.3.2.
Inhaled
13.6.5.4.
Italy Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
13.6.5.4.1.
Pediatrics
13.6.5.4.2.
Adults
13.6.5.4.3.
Geriatric
13.6.6. Nordic Countries
13.6.6.1.
Nordic
Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts,
By TestÂ
13.6.6.1.1.
Sweat
test
13.6.6.1.2.
Genetic
test
13.6.6.1.3.
DNA test
13.6.6.1.4.
Newborn
Screening
13.6.6.1.5.
Chest
X-ray
13.6.6.1.6.
Others
13.6.6.2.
Nordic
Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Treatments
13.6.6.2.1.
Medications
13.6.6.2.1.1. Antibiotics
13.6.6.2.1.2. Anti-inflammatory drugs
13.6.6.2.1.3. Bronchodilators
13.6.6.2.1.4. CFTR modulators
13.6.6.2.1.5. Mucus thinning medications
13.6.6.2.1.6. Others
13.6.6.2.2.
Surgery
13.6.6.2.2.1. Nasal and sinus surgery
13.6.6.2.2.2. Bowel Surgery
13.6.6.2.2.3. Liver transplant
13.6.6.2.2.4. Lung transplant
13.6.6.2.2.5. Others
13.6.6.3.
Nordic
Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Route Of Administration
13.6.6.3.1.
Oral
13.6.6.3.2.
Inhaled
13.6.6.4.
Nordic
Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Age Group
13.6.6.4.1.
Pediatrics
13.6.6.4.2.
Adults
13.6.6.4.3.
Geriatric
13.6.6.5.
Nordic
Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
TestÂ
13.6.7.1.1.
Sweat
test
13.6.7.1.2.
Genetic
test
13.6.7.1.3.
DNA test
13.6.7.1.4.
Newborn
Screening
13.6.7.1.5.
Chest
X-ray
13.6.7.1.6.
Others
13.6.7.2.
Benelux
Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Treatments
13.6.7.2.1.
Medications
13.6.7.2.1.1. Antibiotics
13.6.7.2.1.2. Anti-inflammatory drugs
13.6.7.2.1.3. Bronchodilators
13.6.7.2.1.4. CFTR modulators
13.6.7.2.1.5. Mucus thinning medications
13.6.7.2.1.6. Others
13.6.7.2.2.
Surgery
13.6.7.2.2.1. Nasal and sinus surgery
13.6.7.2.2.2. Bowel Surgery
13.6.7.2.2.3. Liver transplant
13.6.7.2.2.4. Lung transplant
13.6.7.2.2.5. Others
13.6.7.3.
Benelux
Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route Of Administration
13.6.7.3.1.
Oral
13.6.7.3.2.
Inhaled
13.6.7.4.
Benelux
Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Age Group
13.6.7.4.1.
Pediatrics
13.6.7.4.2.
Adults
13.6.7.4.3.
Geriatric
13.6.7.5.
Benelux
Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
TestÂ
13.6.8.1.1.
Sweat
test
13.6.8.1.2.
Genetic
test
13.6.8.1.3.
DNA test
13.6.8.1.4.
Newborn
Screening
13.6.8.1.5.
Chest
X-ray
13.6.8.1.6.
Others
13.6.8.2.
Rest of
Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Treatments
13.6.8.2.1.
Medications
13.6.8.2.1.1. Antibiotics
13.6.8.2.1.2. Anti-inflammatory drugs
13.6.8.2.1.3. Bronchodilators
13.6.8.2.1.4. CFTR modulators
13.6.8.2.1.5. Mucus thinning medications
13.6.8.2.1.6. Others
13.6.8.2.2.
Surgery
13.6.8.2.2.1. Nasal and sinus surgery
13.6.8.2.2.2. Bowel Surgery
13.6.8.2.2.3. Liver transplant
13.6.8.2.2.4. Lung transplant
13.6.8.2.2.5. Others
13.6.8.3.
Rest of
Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route Of Administration
13.6.8.3.1.
Oral
13.6.8.3.2.
Inhaled
13.6.8.4.
Rest of
Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Age Group
13.6.8.4.1.
Pediatrics
13.6.8.4.2.
Adults
13.6.8.4.3.
Geriatric
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By TestÂ
13.7.3. By Treatments
13.7.4. By Route Of Administration
13.7.5. By Age Group
14. Asia Pacific Cystic Fibrosis Therapeutics
Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Asia Pacific Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn)
14.2. Asia Pacific Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By TestÂ
14.2.1. Sweat test
14.2.2. Genetic test
14.2.3. DNA test
14.2.4. Newborn Screening
14.2.5. Chest X-ray
14.2.6. Others
14.3. Asia Pacific Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Treatments
14.3.1. Medications
14.3.1.1.
Antibiotics
14.3.1.2.
Anti-inflammatory
drugs
14.3.1.3.
Bronchodilators
14.3.1.4.
CFTR
modulators
14.3.1.5.
Mucus
thinning medications
14.3.1.6.
Others
14.3.2. Surgery
14.3.2.1.
Nasal
and sinus surgery
14.3.2.2.
Bowel
Surgery
14.3.2.3.
Liver
transplant
14.3.2.4.
Lung
transplant
14.3.2.5.
Others
14.4. Asia Pacific Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route Of Administration
14.4.1. Oral
14.4.2. Inhaled
14.5. Asia Pacific Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Age Group
14.5.1. Pediatrics
14.5.2. Adults
14.5.3. Geriatric
14.6. Asia Pacific Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
14.6.1.1.1.
Sweat
test
14.6.1.1.2.
Genetic
test
14.6.1.1.3.
DNA test
14.6.1.1.4.
Newborn
Screening
14.6.1.1.5.
Chest
X-ray
14.6.1.1.6.
Others
14.6.1.2.
China Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
14.6.1.2.1.
Medications
14.6.1.2.1.1. Antibiotics
14.6.1.2.1.2. Anti-inflammatory drugs
14.6.1.2.1.3. Bronchodilators
14.6.1.2.1.4. CFTR modulators
14.6.1.2.1.5. Mucus thinning medications
14.6.1.2.1.6. Others
14.6.1.2.2.
Surgery
14.6.1.2.2.1. Nasal and sinus surgery
14.6.1.2.2.2. Bowel Surgery
14.6.1.2.2.3. Liver transplant
14.6.1.2.2.4. Lung transplant
14.6.1.2.2.5. Others
14.6.1.3.
China Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
14.6.1.3.1.
Oral
14.6.1.3.2.
Inhaled
14.6.1.4.
China Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
14.6.1.4.1.
Pediatrics
14.6.1.4.2.
Adults
14.6.1.4.3.
Geriatric
14.6.2. Japan
14.6.2.1.
Japan Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
14.6.2.1.1.
Sweat
test
14.6.2.1.2.
Genetic
test
14.6.2.1.3.
DNA test
14.6.2.1.4.
Newborn
Screening
14.6.2.1.5.
Chest
X-ray
14.6.2.1.6.
Others
14.6.2.2.
Japan Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
14.6.2.2.1.
Medications
14.6.2.2.1.1. Antibiotics
14.6.2.2.1.2. Anti-inflammatory drugs
14.6.2.2.1.3. Bronchodilators
14.6.2.2.1.4. CFTR modulators
14.6.2.2.1.5. Mucus thinning medications
14.6.2.2.1.6. Others
14.6.2.2.2.
Surgery
14.6.2.2.2.1. Nasal and sinus surgery
14.6.2.2.2.2. Bowel Surgery
14.6.2.2.2.3. Liver transplant
14.6.2.2.2.4. Lung transplant
14.6.2.2.2.5. Others
14.6.2.3.
Japan Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
14.6.2.3.1.
Oral
14.6.2.3.2.
Inhaled
14.6.2.4.
Japan Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
14.6.2.4.1.
Pediatrics
14.6.2.4.2.
Adults
14.6.2.4.3.
Geriatric
14.6.3. India
14.6.3.1.
India Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
14.6.3.1.1.
Sweat test
14.6.3.1.2.
Genetic
test
14.6.3.1.3.
DNA test
14.6.3.1.4.
Newborn
Screening
14.6.3.1.5.
Chest
X-ray
14.6.3.1.6.
Others
14.6.3.2.
India Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
14.6.3.2.1.
Medications
14.6.3.2.1.1. Antibiotics
14.6.3.2.1.2. Anti-inflammatory drugs
14.6.3.2.1.3. Bronchodilators
14.6.3.2.1.4. CFTR modulators
14.6.3.2.1.5. Mucus thinning medications
14.6.3.2.1.6. Others
14.6.3.2.2.
Surgery
14.6.3.2.2.1. Nasal and sinus surgery
14.6.3.2.2.2. Bowel Surgery
14.6.3.2.2.3. Liver transplant
14.6.3.2.2.4. Lung transplant
14.6.3.2.2.5. Others
14.6.3.3.
India Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
14.6.3.3.1.
Oral
14.6.3.3.2.
Inhaled
14.6.3.4.
India Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
14.6.3.4.1.
Pediatrics
14.6.3.4.2.
Adults
14.6.3.4.3.
Geriatric
14.6.4. New Zealand
14.6.4.1.
New
Zealand Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
TestÂ
14.6.4.1.1.
Sweat
test
14.6.4.1.2.
Genetic
test
14.6.4.1.3.
DNA test
14.6.4.1.4.
Newborn
Screening
14.6.4.1.5.
Chest
X-ray
14.6.4.1.6.
Others
14.6.4.2.
New
Zealand Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Treatments
14.6.4.2.1.
Medications
14.6.4.2.1.1. Antibiotics
14.6.4.2.1.2. Anti-inflammatory drugs
14.6.4.2.1.3. Bronchodilators
14.6.4.2.1.4. CFTR modulators
14.6.4.2.1.5. Mucus thinning medications
14.6.4.2.1.6. Others
14.6.4.2.2.
Surgery
14.6.4.2.2.1. Nasal and sinus surgery
14.6.4.2.2.2. Bowel Surgery
14.6.4.2.2.3. Liver transplant
14.6.4.2.2.4. Lung transplant
14.6.4.2.2.5. Others
14.6.4.3.
New
Zealand Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route Of Administration
14.6.4.3.1.
Oral
14.6.4.3.2.
Inhaled
14.6.4.4.
New
Zealand Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Age Group
14.6.4.4.1.
Pediatrics
14.6.4.4.2.
Adults
14.6.4.4.3.
Geriatric
14.6.5. Australia
14.6.5.1.
Australia
Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
TestÂ
14.6.5.1.1.
Sweat
test
14.6.5.1.2.
Genetic
test
14.6.5.1.3.
DNA test
14.6.5.1.4.
Newborn
Screening
14.6.5.1.5.
Chest
X-ray
14.6.5.1.6.
Others
14.6.5.2.
Australia
Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Treatments
14.6.5.2.1.
Medications
14.6.5.2.1.1. Antibiotics
14.6.5.2.1.2. Anti-inflammatory drugs
14.6.5.2.1.3. Bronchodilators
14.6.5.2.1.4. CFTR modulators
14.6.5.2.1.5. Mucus thinning medications
14.6.5.2.1.6. Others
14.6.5.2.2.
Surgery
14.6.5.2.2.1. Nasal and sinus surgery
14.6.5.2.2.2. Bowel Surgery
14.6.5.2.2.3. Liver transplant
14.6.5.2.2.4. Lung transplant
14.6.5.2.2.5. Others
14.6.5.3.
Australia
Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
14.6.5.3.1.
Oral
14.6.5.3.2.
Inhaled
14.6.5.4.
Australia
Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age
Group
14.6.5.4.1.
Pediatrics
14.6.5.4.2.
Adults
14.6.5.4.3.
Geriatric
14.6.6. South Korea
14.6.6.1.
South
Korea Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
TestÂ
14.6.6.1.1.
Sweat
test
14.6.6.1.2.
Genetic
test
14.6.6.1.3.
DNA test
14.6.6.1.4.
Newborn
Screening
14.6.6.1.5.
Chest
X-ray
14.6.6.1.6.
Others
14.6.6.2.
South
Korea Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Treatments
14.6.6.2.1.
Medications
14.6.6.2.1.1. Antibiotics
14.6.6.2.1.2. Anti-inflammatory drugs
14.6.6.2.1.3. Bronchodilators
14.6.6.2.1.4. CFTR modulators
14.6.6.2.1.5. Mucus thinning medications
14.6.6.2.1.6. Others
14.6.6.2.2.
Surgery
14.6.6.2.2.1. Nasal and sinus surgery
14.6.6.2.2.2. Bowel Surgery
14.6.6.2.2.3. Liver transplant
14.6.6.2.2.4. Lung transplant
14.6.6.2.2.5. Others
14.6.6.3.
South
Korea Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route Of Administration
14.6.6.3.1.
Oral
14.6.6.3.2.
Inhaled
14.6.6.4.
South
Korea Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Age Group
14.6.6.4.1.
Pediatrics
14.6.6.4.2.
Adults
14.6.6.4.3.
Geriatric
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
TestÂ
14.6.7.1.1.
Sweat
test
14.6.7.1.2.
Genetic
test
14.6.7.1.3.
DNA test
14.6.7.1.4.
Newborn
Screening
14.6.7.1.5.
Chest
X-ray
14.6.7.1.6.
Others
14.6.7.2.
Southeast
Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
14.6.7.2.1.
Medications
14.6.7.2.1.1. Antibiotics
14.6.7.2.1.2. Anti-inflammatory drugs
14.6.7.2.1.3. Bronchodilators
14.6.7.2.1.4. CFTR modulators
14.6.7.2.1.5. Mucus thinning medications
14.6.7.2.1.6. Others
14.6.7.2.2.
Surgery
14.6.7.2.2.1. Nasal and sinus surgery
14.6.7.2.2.2. Bowel Surgery
14.6.7.2.2.3. Liver transplant
14.6.7.2.2.4. Lung transplant
14.6.7.2.2.5. Others
14.6.7.3.
Southeast
Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route Of Administration
14.6.7.3.1.
Oral
14.6.7.3.2.
Inhaled
14.6.7.4.
Southeast
Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age
Group
14.6.7.4.1.
Pediatrics
14.6.7.4.2.
Adults
14.6.7.4.3.
Geriatric
14.6.7.5.
Southeast
Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By TestÂ
14.6.8.1.1.
Sweat
test
14.6.8.1.2.
Genetic
test
14.6.8.1.3.
DNA test
14.6.8.1.4.
Newborn
Screening
14.6.8.1.5.
Chest
X-ray
14.6.8.1.6.
Others
14.6.8.2.
Rest of
Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Treatments
14.6.8.2.1.
Medications
14.6.8.2.1.1. Antibiotics
14.6.8.2.1.2. Anti-inflammatory drugs
14.6.8.2.1.3. Bronchodilators
14.6.8.2.1.4. CFTR modulators
14.6.8.2.1.5. Mucus thinning medications
14.6.8.2.1.6. Others
14.6.8.2.2.
Surgery
14.6.8.2.2.1. Nasal and sinus surgery
14.6.8.2.2.2. Bowel Surgery
14.6.8.2.2.3. Liver transplant
14.6.8.2.2.4. Lung transplant
14.6.8.2.2.5. Others
14.6.8.3.
Rest of
Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Route Of Administration
14.6.8.3.1.
Oral
14.6.8.3.2.
Inhaled
14.6.8.4.
Rest of
Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Age Group
14.6.8.4.1.
Pediatrics
14.6.8.4.2.
Adults
14.6.8.4.3.
Geriatric
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By TestÂ
14.7.3. By Treatments
14.7.4. By Route Of Administration
14.7.5. By Age Group
15. Middle East and Africa Cystic Fibrosis
Therapeutics Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Middle East and Africa Cystic Fibrosis
Therapeutics Market Revenue (US$ Mn)
15.2. Middle East and Africa Cystic Fibrosis
Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
15.2.1. Sweat test
15.2.2. Genetic test
15.2.3. DNA test
15.2.4. Newborn Screening
15.2.5. Chest X-ray
15.2.6. Others
15.3. Middle East and Africa Cystic Fibrosis
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
15.3.1. Medications
15.3.1.1.
Antibiotics
15.3.1.2.
Anti-inflammatory
drugs
15.3.1.3.
Bronchodilators
15.3.1.4.
CFTR
modulators
15.3.1.5.
Mucus
thinning medications
15.3.1.6.
Others
15.3.2. Surgery
15.3.2.1.
Nasal
and sinus surgery
15.3.2.2.
Bowel
Surgery
15.3.2.3.
Liver
transplant
15.3.2.4.
Lung
transplant
15.3.2.5.
Others
15.4. Middle East and Africa Cystic Fibrosis
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of Administration
15.4.1. Oral
15.4.2. Inhaled
15.5. Middle East and Africa Cystic Fibrosis
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
15.5.1. Pediatrics
15.5.2. Adults
15.5.3. Geriatric
15.6. Middle East and Africa Cystic Fibrosis
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
TestÂ
15.6.1.1.1.
Sweat
test
15.6.1.1.2.
Genetic
test
15.6.1.1.3.
DNA test
15.6.1.1.4.
Newborn
Screening
15.6.1.1.5.
Chest
X-ray
15.6.1.1.6.
Others
15.6.1.2.
Saudi
Arabia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Treatments
15.6.1.2.1.
Medications
15.6.1.2.1.1. Antibiotics
15.6.1.2.1.2. Anti-inflammatory drugs
15.6.1.2.1.3. Bronchodilators
15.6.1.2.1.4. CFTR modulators
15.6.1.2.1.5. Mucus thinning medications
15.6.1.2.1.6. Others
15.6.1.2.2.
Surgery
15.6.1.2.2.1. Nasal and sinus surgery
15.6.1.2.2.2. Bowel Surgery
15.6.1.2.2.3. Liver transplant
15.6.1.2.2.4. Lung transplant
15.6.1.2.2.5. Others
15.6.1.3.
Saudi
Arabia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route Of Administration
15.6.1.3.1.
Oral
15.6.1.3.2.
Inhaled
15.6.1.4.
Saudi
Arabia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Age Group
15.6.1.4.1.
Pediatrics
15.6.1.4.2.
Adults
15.6.1.4.3.
Geriatric
15.6.2. UAE
15.6.2.1.
UAE Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
15.6.2.1.1.
Sweat
test
15.6.2.1.2.
Genetic
test
15.6.2.1.3.
DNA test
15.6.2.1.4.
Newborn
Screening
15.6.2.1.5.
Chest
X-ray
15.6.2.1.6.
Others
15.6.2.2.
UAE Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
15.6.2.2.1.
Medications
15.6.2.2.1.1. Antibiotics
15.6.2.2.1.2. Anti-inflammatory drugs
15.6.2.2.1.3. Bronchodilators
15.6.2.2.1.4. CFTR modulators
15.6.2.2.1.5. Mucus thinning medications
15.6.2.2.1.6. Others
15.6.2.2.2.
Surgery
15.6.2.2.2.1. Nasal and sinus surgery
15.6.2.2.2.2. Bowel Surgery
15.6.2.2.2.3. Liver transplant
15.6.2.2.2.4. Lung transplant
15.6.2.2.2.5. Others
15.6.2.3.
UAE Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
15.6.2.3.1.
Oral
15.6.2.3.2.
Inhaled
15.6.2.4.
UAE Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
15.6.2.4.1.
Pediatrics
15.6.2.4.2.
Adults
15.6.2.4.3.
Geriatric
15.6.3. Egypt
15.6.3.1.
Egypt Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
15.6.3.1.1.
Sweat
test
15.6.3.1.2.
Genetic
test
15.6.3.1.3.
DNA test
15.6.3.1.4.
Newborn
Screening
15.6.3.1.5.
Chest
X-ray
15.6.3.1.6.
Others
15.6.3.2.
Egypt Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
15.6.3.2.1.
Medications
15.6.3.2.1.1. Antibiotics
15.6.3.2.1.2. Anti-inflammatory drugs
15.6.3.2.1.3. Bronchodilators
15.6.3.2.1.4. CFTR modulators
15.6.3.2.1.5. Mucus thinning medications
15.6.3.2.1.6. Others
15.6.3.2.2.
Surgery
15.6.3.2.2.1. Nasal and sinus surgery
15.6.3.2.2.2. Bowel Surgery
15.6.3.2.2.3. Liver transplant
15.6.3.2.2.4. Lung transplant
15.6.3.2.2.5. Others
15.6.3.3.
Egypt Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
15.6.3.3.1.
Oral
15.6.3.3.2.
Inhaled
15.6.3.4.
Egypt Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
15.6.3.4.1.
Pediatrics
15.6.3.4.2.
Adults
15.6.3.4.3.
Geriatric
15.6.4. Kuwait
15.6.4.1.
Kuwait Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
15.6.4.1.1.
Sweat
test
15.6.4.1.2.
Genetic
test
15.6.4.1.3.
DNA test
15.6.4.1.4.
Newborn
Screening
15.6.4.1.5.
Chest
X-ray
15.6.4.1.6.
Others
15.6.4.2.
Kuwait Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
15.6.4.2.1.
Medications
15.6.4.2.1.1. Antibiotics
15.6.4.2.1.2. Anti-inflammatory drugs
15.6.4.2.1.3. Bronchodilators
15.6.4.2.1.4. CFTR modulators
15.6.4.2.1.5. Mucus thinning medications
15.6.4.2.1.6. Others
15.6.4.2.2.
Surgery
15.6.4.2.2.1. Nasal and sinus surgery
15.6.4.2.2.2. Bowel Surgery
15.6.4.2.2.3. Liver transplant
15.6.4.2.2.4. Lung transplant
15.6.4.2.2.5. Others
15.6.4.3.
Kuwait Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
15.6.4.3.1.
Oral
15.6.4.3.2.
Inhaled
15.6.4.4.
Kuwait Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
15.6.4.4.1.
Pediatrics
15.6.4.4.2.
Adults
15.6.4.4.3.
Geriatric
15.6.5. South Africa
15.6.5.1.
South
Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
TestÂ
15.6.5.1.1.
Sweat
test
15.6.5.1.2.
Genetic
test
15.6.5.1.3.
DNA test
15.6.5.1.4.
Newborn
Screening
15.6.5.1.5.
Chest
X-ray
15.6.5.1.6.
Others
15.6.5.2.
South
Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Treatments
15.6.5.2.1.
Medications
15.6.5.2.1.1. Antibiotics
15.6.5.2.1.2. Anti-inflammatory drugs
15.6.5.2.1.3. Bronchodilators
15.6.5.2.1.4. CFTR modulators
15.6.5.2.1.5. Mucus thinning medications
15.6.5.2.1.6. Others
15.6.5.2.2.
Surgery
15.6.5.2.2.1. Nasal and sinus surgery
15.6.5.2.2.2. Bowel Surgery
15.6.5.2.2.3. Liver transplant
15.6.5.2.2.4. Lung transplant
15.6.5.2.2.5. Others
15.6.5.3.
South
Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route Of Administration
15.6.5.3.1.
Oral
15.6.5.3.2.
Inhaled
15.6.5.4.
South
Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Age Group
15.6.5.4.1.
Pediatrics
15.6.5.4.2.
Adults
15.6.5.4.3.
Geriatric
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)
and Forecasts, By TestÂ
15.6.6.1.1.
Sweat
test
15.6.6.1.2.
Genetic
test
15.6.6.1.3.
DNA test
15.6.6.1.4.
Newborn
Screening
15.6.6.1.5.
Chest
X-ray
15.6.6.1.6.
Others
15.6.6.2.
Rest of
Middle East & Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Treatments
15.6.6.2.1.
Medications
15.6.6.2.1.1. Antibiotics
15.6.6.2.1.2. Anti-inflammatory drugs
15.6.6.2.1.3. Bronchodilators
15.6.6.2.1.4. CFTR modulators
15.6.6.2.1.5. Mucus thinning medications
15.6.6.2.1.6. Others
15.6.6.2.2.
Surgery
15.6.6.2.2.1. Nasal and sinus surgery
15.6.6.2.2.2. Bowel Surgery
15.6.6.2.2.3. Liver transplant
15.6.6.2.2.4. Lung transplant
15.6.6.2.2.5. Others
15.6.6.3.
Rest of
Middle East & Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Route Of Administration
15.6.6.3.1.
Oral
15.6.6.3.2.
Inhaled
15.6.6.4.
Rest of
Middle East & Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)
and Forecasts, By Age Group
15.6.6.4.1.
Pediatrics
15.6.6.4.2.
Adults
15.6.6.4.3.
Geriatric
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By TestÂ
15.7.3. By Treatments
15.7.4. By Route Of Administration
15.7.5. By Age Group
16. Latin America Cystic Fibrosis Therapeutics
Market Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Latin America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn)
16.2. Latin America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By TestÂ
16.2.1. Sweat test
16.2.2. Genetic test
16.2.3. DNA test
16.2.4. Newborn Screening
16.2.5. Chest X-ray
16.2.6. Others
16.3. Latin America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Treatments
16.3.1. Medications
16.3.1.1.
Antibiotics
16.3.1.2.
Anti-inflammatory
drugs
16.3.1.3.
Bronchodilators
16.3.1.4.
CFTR
modulators
16.3.1.5.
Mucus
thinning medications
16.3.1.6.
Others
16.3.2. Surgery
16.3.2.1.
Nasal
and sinus surgery
16.3.2.2.
Bowel
Surgery
16.3.2.3.
Liver
transplant
16.3.2.4.
Lung
transplant
16.3.2.5.
Others
16.4. Latin America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route Of Administration
16.4.1. Oral
16.4.2. Inhaled
16.5. Latin America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Age Group
16.5.1. Pediatrics
16.5.2. Adults
16.5.3. Geriatric
16.6. Latin America Cystic Fibrosis Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By TestÂ
16.6.1.1.1.
Sweat
test
16.6.1.1.2.
Genetic
test
16.6.1.1.3.
DNA test
16.6.1.1.4.
Newborn
Screening
16.6.1.1.5.
Chest
X-ray
16.6.1.1.6.
Others
16.6.1.2.
Brazil Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Treatments
16.6.1.2.1.
Medications
16.6.1.2.1.1. Antibiotics
16.6.1.2.1.2. Anti-inflammatory drugs
16.6.1.2.1.3. Bronchodilators
16.6.1.2.1.4. CFTR modulators
16.6.1.2.1.5. Mucus thinning medications
16.6.1.2.1.6. Others
16.6.1.2.2.
Surgery
16.6.1.2.2.1. Nasal and sinus surgery
16.6.1.2.2.2. Bowel Surgery
16.6.1.2.2.3. Liver transplant
16.6.1.2.2.4. Lung transplant
16.6.1.2.2.5. Others
16.6.1.3.
Brazil Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
16.6.1.3.1.
Oral
16.6.1.3.2.
Inhaled
16.6.1.4.
Brazil Cystic
Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age Group
16.6.1.4.1.
Pediatrics
16.6.1.4.2.
Adults
16.6.1.4.3.
Geriatric
16.6.2. Argentina
16.6.2.1.
Argentina
Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
TestÂ
16.6.2.1.1.
Sweat
test
16.6.2.1.2.
Genetic
test
16.6.2.1.3.
DNA test
16.6.2.1.4.
Newborn
Screening
16.6.2.1.5.
Chest
X-ray
16.6.2.1.6.
Others
16.6.2.2.
Argentina
Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Treatments
16.6.2.2.1.
Medications
16.6.2.2.1.1. Antibiotics
16.6.2.2.1.2. Anti-inflammatory drugs
16.6.2.2.1.3. Bronchodilators
16.6.2.2.1.4. CFTR modulators
16.6.2.2.1.5. Mucus thinning medications
16.6.2.2.1.6. Others
16.6.2.2.2.
Surgery
16.6.2.2.2.1. Nasal and sinus surgery
16.6.2.2.2.2. Bowel Surgery
16.6.2.2.2.3. Liver transplant
16.6.2.2.2.4. Lung transplant
16.6.2.2.2.5. Others
16.6.2.3.
Argentina
Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route Of
Administration
16.6.2.3.1.
Oral
16.6.2.3.2.
Inhaled
16.6.2.4.
Argentina
Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Age
Group
16.6.2.4.1.
Pediatrics
16.6.2.4.2.
Adults
16.6.2.4.3.
Geriatric
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By TestÂ
16.6.3.1.1.
Sweat
test
16.6.3.1.2.
Genetic
test
16.6.3.1.3.
DNA test
16.6.3.1.4.
Newborn
Screening
16.6.3.1.5.
Chest
X-ray
16.6.3.1.6.
Others
16.6.3.2.
Rest of
Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Treatments
16.6.3.2.1.
Medications
16.6.3.2.1.1. Antibiotics
16.6.3.2.1.2. Anti-inflammatory drugs
16.6.3.2.1.3. Bronchodilators
16.6.3.2.1.4. CFTR modulators
16.6.3.2.1.5. Mucus thinning medications
16.6.3.2.1.6. Others
16.6.3.2.2.
Surgery
16.6.3.2.2.1. Nasal and sinus surgery
16.6.3.2.2.2. Bowel Surgery
16.6.3.2.2.3. Liver transplant
16.6.3.2.2.4. Lung transplant
16.6.3.2.2.5. Others
16.6.3.3.
Rest of
Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Route Of Administration
16.6.3.3.1.
Oral
16.6.3.3.2.
Inhaled
16.6.3.4.
Rest of
Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Age Group
16.6.3.4.1.
Pediatrics
16.6.3.4.2.
Adults
16.6.3.4.3.
Geriatric
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By TestÂ
16.7.3. By Treatments
16.7.4. By Route Of Administration
16.7.5. By Age Group
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2021
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. AbbVie Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Alaxia
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Alcresta Therapeutics, Inc
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. CHIESI Farmaceutici S.p.A
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Genentech, Inc.
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Gilead Sciences, Inc.
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Horizon Therapeutics plc
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Laurent Pharmaceuticals IncÂ
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Mylan N.V.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Novartis AG
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Pharmaxis Ltd
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Teva UK Limited
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Vertex Pharmaceuticals Incorporated
18.13.1. Company Details
18.13.2. Company Overview
18.13.3. Product Offerings
18.13.4. Key Developments
18.13.5. Financial Analysis
18.13.6. SWOT Analysis
18.13.7. Business Strategies
18.14. Other Market Participants
19. Key Findings
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
